Core Insights - Cytek Biosciences reported a total revenue of $45.6 million for Q2 2025, reflecting a 2% decrease compared to Q2 2024, primarily due to lower product revenue in EMEA and APAC regions, although service revenue showed growth globally and in the U.S. [5][10] - The company launched the Cytek Aurora Evo system, which is expected to enhance the adoption of its solutions and strengthen its market position [3][10] - Cytek's total recurring revenue, which includes service and reagent revenues, grew by 16% year-over-year, accounting for 32% of the total revenue over the last 12 months [10] Financial Performance - GAAP gross profit for Q2 2025 was $23.9 million, a 6% decrease from Q2 2024, with a gross profit margin of 52% compared to 55% in the previous year [6][10] - Operating expenses increased by 2% to $34.5 million, with R&D expenses decreasing by 12% to $8.8 million, while general and administrative expenses rose by 16% to $13.5 million [7][8] - The net loss for Q2 2025 was $5.6 million, an improvement from a net loss of $10.4 million in Q2 2024 [8][10] Market Outlook - The company narrowed its 2025 revenue guidance to a range of $196 million to $205 million, indicating a potential growth of -2% to +2% compared to 2024 [12] - Cytek aims to expand its installed base globally and enhance recurring revenue through its service and reagent businesses, while focusing on innovation to redefine industry standards [4][10]

Core Viewpoint - Cytek Biosciences, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, indicating its active engagement in the healthcare investment community [1]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that specializes in high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [3]. - The company offers a comprehensive suite of products including the Cytek Aurora™, Northern Lights™, and Cytek Orion™ systems, as well as flow cytometers and imaging products under the Amnis and Guava brands [3]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [3]. Upcoming Events - Cytek management is scheduled for a fireside chat on June 11 at 11:40 a.m. Pacific Time, which will be accessible via a live and archived webcast on the company's website [2].

Core Insights - Cytek Biosciences reported a total revenue of $41.5 million for Q1 2025, reflecting a 7.6% decrease compared to Q1 2024, primarily due to a slowdown in product sales in the US and EMEA regions, although this was partially offset by growth in the APAC region and strong service revenue globally [4][8] - The company experienced a gross profit of $20.2 million in Q1 2025, which is a 12% decrease from the previous year, resulting in a GAAP gross profit margin of 49% compared to 51% in Q1 2024 [5][20] - Operating expenses increased by 4.1% to $35.1 million, with general and administrative expenses rising significantly from $11.4 million in Q1 2024 to $12.9 million in Q1 2025 [6][7] - The net loss for Q1 2025 was $11.4 million, compared to a net loss of $6.2 million in Q1 2024, indicating a worsening financial position [7][20] - Cytek's cash and marketable securities totaled $265.6 million as of March 31, 2025, down from $277.9 million at the end of 2024, despite share repurchases of $10.6 million during the quarter [9][20] - The company has revised its full-year 2025 revenue guidance to a range of $196 million to $210 million, which represents a potential decline of 2% to growth of 5% compared to 2024 [10] Financial Performance - Total revenue for Q1 2025 was $41.5 million, with product revenue at $28.1 million and service revenue at $13.3 million [20] - Gross profit for the quarter was $20.2 million, leading to a GAAP gross margin of 49% [5][20] - Operating expenses were $35.1 million, with research and development expenses at $9.7 million and sales and marketing expenses remaining flat at $12.5 million [6][20] - The adjusted EBITDA loss for Q1 2025 was $3.3 million, compared to a loss of $0.7 million in Q1 2024 [8][20] Strategic Developments - Cytek expanded its installed base to 3,149 instruments, adding 115 units in Q1 2025, and commenced operations in Singapore to enhance manufacturing capacity [8] - The company launched the Cytek Muse Micro instrument, aimed at providing an affordable option for simplified flow cytometry [8] - Cytek repurchased $10.6 million of its common stock during the first quarter, indicating a commitment to returning value to shareholders [8]

Core Insights - Cytek Biosciences is committed to advancing cell analysis through its patented Full Spectrum Profiling™ (FSP) technology, which will be showcased at key industry events such as CYTO 2025 and IMMUNOLOGY2025 [1][2][5] Company Overview - Cytek Biosciences, Inc. (Nasdaq: CTKB) is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity tools [6][7] - The company’s FSP technology enhances multiplexing capabilities with precision and sensitivity, positioning it as a pioneer in spectral flow cytometry [6][2] Industry Events - At IMMUNOLOGY2025, Cytek will present its complete cell analysis solutions, including instruments, reagents, and software, aimed at advancing research and discovery [3][4] - The company will also host a workshop on in-depth characterization of mouse immune responses during the event [4] - CYTO 2025 will feature Cytek as a Platinum sponsor, where it will showcase technology designed to accelerate scientific discovery [4][5] Strategic Goals - Cytek aims to make flow cytometry technology more accessible and scalable, unlocking new opportunities in high-growth areas such as immunology, oncology, and cell therapy [2][5] - The company emphasizes its commitment to delivering innovative and flexible solutions to empower researchers and accelerate breakthroughs in scientific advancement [5]